The Latest Cardiac and Vascular News
– Large, Randomized Controlled ADVENT Trial Designed to Establish New Gold Standard for AF Ablation – MENLO PARK, Calif., Dec. 17, 2020 /PRNewswire/ – FARAPULSE Inc. (“FARAPULSE” or “the Company”) today announced the U.S. Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to initiate its U.S. pivotal ADVENT […]
I Peace’s GMP-grade iPSCs are key to manufacture Avery Therapeutics’ MyCardia™, a proprietary tissue-engineered heart graft developed to treat heart failure TUCSON, Ariz. and PALO ALTO, Calif., Dec. 16, 2020 /PRNewswire/ — Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo […]
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) — BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP™ Heart Failure Trial. The DSMB based its […]
REDUCER I Study Shows Improvement in Chest Pain Symptoms VANCOUVER and MINNEAPOLIS, Dec. 17, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI), has published online a peer-reviewed study announcing […]
Authors report that celiprolol may have a protective effect in COL3A1-positive vEDS patients NEWTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today […]
Adds to Portfolio of 40 Patents for Catheter-Based Technology That Leverages Power of Body’s Natural Fluid Removal Process GALWAY, Ireland–(BUSINESS WIRE)–WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company a new patent for […]
Appointment reflects progress of Company’s early-stage pipeline toward the clinic BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer and […]
First-of-its-kind health engagement experience will deliver evidence-based content, resources, and tools to thousands of individuals experiencing heart failure SAN MATEO, Calif.–(BUSINESS WIRE)–Evidation Health and the American College of Cardiology (ACC) announced today they are joining forces to co-develop and launch Achievement for Heart Health–a health engagement experience built on Evidation’s Achievement platform–that will make […]
Company Advancing Proprietary Machine Learning to Improve Care in Cardiology TORONTO–(BUSINESS WIRE)–Analytics 4 Life today announced the appointment of Scott Burger to Chief Commercial Officer and Vice President. Scott will lead the commercialization efforts of the CorVista® System, a non-invasive point-of-care solution that allows physicians to rapidly assess heart function. […]
– NILEMDO® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients – – Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies1,2 – […]
